Germany: the S2k guideline and the self-determination law

How does Germany's 2024 guideline on gender incongruence in minors compare with the Nordic reviews, and what did the self-determination law change?

Germany’s position is frequently presented as a direct answer to the Nordic reappraisals of paediatric gender medicine. That is only partly accurate. Germany has two distinct policy tracks: a clinical guideline for assessment and treatment, and a civil-status law on the legal recording of sex and names. The two are politically connected in public debate, but legally separate.

Background

Germany’s position is frequently presented as a direct answer to the Nordic reappraisals of paediatric gender medicine. That is only partly accurate. Germany has two distinct policy tracks: a clinical guideline for assessment and treatment, and a civil-status law on the legal recording of sex and names. The two are politically connected in public debate, but legally separate.

A date correction matters. The German S2k guideline was not finally published in 2024. A draft was discussed in March 2024; the final guideline was adopted in March 2025 and the current short version is dated 24 June 2025. It is registered by the Association of the Scientific Medical Societies in Germany, the AWMF. The title is Gender Incongruence and Gender Dysphoria in Childhood and Adolescence: Diagnosis and Treatment. Its designation, S2k, means a structured consensus guideline rather than the highest German S3 level, which requires both structured consensus and a fully formal evidence-based process.

The Self-Determination Act, or Selbstbestimmungsgesetz, is a separate statute. It replaced the old Transsexuals Act procedure for changing a person’s legal sex entry and first names. The old route involved the courts and expert assessments. The new route is a declaration to a civil registry office, subject to procedural requirements. Crucially, section 1(2) states that medical measures are not governed by the Act. The law neither authorises nor prohibits puberty blockers, cross-sex hormones or surgery. (Self-Determination Act, 2024). ([gesetze-im-internet.de](https://www.gesetze-im-internet.de/sbgg/BJNR0CE0B0024.html))

What the documents say

The German S2k guideline

The S2k guideline acknowledges significant professional uncertainty and controversy. It recommends individual assessment, specialist knowledge, multidisciplinary involvement and attention to mental-health difficulties, developmental history and family circumstances. It also says that those involved in decisions on body-modifying medical interventions should have specialist knowledge and several years’ experience with adolescents presenting with gender incongruence. (AWMF S2k Guideline, 2025). ([register.awmf.org](https://register.awmf.org/assets/guidelines/028-014k_S2k_Geschlechtsinkongruenz-Geschlechtsdysphorie-Kinder-Jugendliche_2025-06pdf.pdf))

For adolescents, the guideline does not impose a blanket ban on puberty suppression or cross-sex hormones. Instead, it permits an individually justified indication where gender incongruence is persistent and specified conditions are met. For cross-sex hormones, it calls for stable or persistent gender incongruence, dysphoric distress present after puberty begins, several years of transgender feelings, and a careful assessment involving experienced psychiatric or psychotherapeutic professionals, the young person and parents or carers. It recommends a social trial of the desired gender role before cross-sex hormones where compatible with protection from discrimination. (AWMF S2k Guideline, 2025). ([register.awmf.org](https://register.awmf.org/assets/guidelines/028-014k_S2k_Geschlechtsinkongruenz-Geschlechtsdysphorie-Kinder-Jugendliche_2025-06pdf.pdf))

The guideline does not claim certainty. It says that uncontrolled cohort studies suggest favourable mental-health and life-satisfaction outcomes when cross-sex hormones form part of treatment, but explicitly classifies that evidence as uncertain. It also requires counselling on potential effects on fertility, growth, bone metabolism, later sexual sensation and the feasibility of future genital surgery. Puberty suppression should be limited in duration on an individual basis to reduce possible long-term physical effects, particularly on bone mineralisation. (AWMF S2k Guideline, 2025). ([register.awmf.org](https://register.awmf.org/assets/guidelines/028-014k_S2k_Geschlechtsinkongruenz-Geschlechtsdysphorie-Kinder-Jugendliche_2025-06pdf.pdf))

There are also recorded dissents. The German Society for Psychiatry, Psychotherapy, Psychosomatics and Neurology, the DGPPN, entered several minority opinions seeking firmer wording on comprehensive psychiatric and psychotherapeutic assessment, co-occurring disorders and research participation. Patient organisations, meanwhile, dissented from the newly added requirement of “several years” of transgender feelings for cross-sex hormones. These are important records because they show that a high percentage of formal consensus did not mean unanimity on the safeguards or thresholds. (AWMF S2k Guideline, 2025). ([register.awmf.org](https://register.awmf.org/assets/guidelines/028-014k_S2k_Geschlechtsinkongruenz-Geschlechtsdysphorie-Kinder-Jugendliche_2025-06pdf.pdf))

The Nordic reviews

Finland’s COHERE took a more restrictive approach in 2020. It placed psychosocial support and treatment of psychiatric symptoms at the centre of care; assessment and medical treatment were centralised in the specialist clinics at Helsinki University Hospital and Tampere University Hospital. COHERE allowed puberty suppression case by case for carefully assessed children with persistent distress emerging before puberty. Cross-sex hormonal interventions before 18 could be considered only after thorough individual assessment, where a permanent cross-sex identity and severe dysphoria could be established, the young person understood irreversible treatment and lifelong hormone therapy, and there were no contraindications. Surgery was excluded for minors. COHERE also called for data on benefits, harms and regret. (COHERE Finland, 2020). ([palveluvalikoima.fi](https://palveluvalikoima.fi/documents/1237350/22895008/Summary_minors_en.pdf/aaf9a6e7-b970-9de9-165c-abedfae46f2e/Summary_minors_en.pdf))

Sweden’s SBU review examined puberty blockers and cross-sex hormones started before 18. It identified no randomised studies and judged the available observational evidence vulnerable to bias and imprecision. Sweden’s National Board of Health and Welfare subsequently stated that the risks of puberty blockers and cross-sex hormones for young people were likely to outweigh the possible benefits in most cases, while allowing individual treatment in exceptional cases under specified criteria. Karolinska University Hospital had already limited new hormonal treatment for under-18s to ethically approved clinical research, citing weak evidence, patient safety and consent concerns. (SBU, 2022; Socialstyrelsen, 2022; Karolinska University Hospital, 2021). ([sbu.se](https://www.sbu.se/342?pub=90213))

Norway’s UKOM report did not itself create a new treatment ban. It described an inconclusive evidence base, stressed patient safety, multidisciplinary competence and the need for research and systematic follow-up. Its core concern was that a high-specialist field requires services able to assess complexity rather than simply accelerate a pathway towards medical treatment. (UKOM, 2023). ([ukom.no](https://ukom.no/rapporter/pasientsikkerhet-for-barn-og-unge-med-kjonnsinkongruens?printPdf=true))

The Self-Determination Act

From 1 November 2024, adults can change their legal sex entry and first names by declaring at a registry office that the chosen entry, or removal of the entry, best reflects their gender identity and that they understand the consequences. They must register their intention three months in advance. For adults, a further declaration is normally barred for one year.

For minors, the legal position is not simple self-declaration. A young person aged 14 or older makes the declaration personally but needs the consent of a legal representative and must state that they have received advice. If consent is refused, the family court may substitute consent only where the change does not conflict with the child’s welfare. For a child under 14, the legal representative makes the declaration; from age five, the child’s agreement is required. The Act also preserves sex-based relevance in healthcare where bodily characteristics matter, and leaves access rules for premises, events and sport to other legal and organisational rules. (Self-Determination Act, 2024). ([gesetze-im-internet.de](https://www.gesetze-im-internet.de/sbgg/BJNR0CE0B0024.html))

The positions

Supporters of the German guideline argue that medicine should not deny individually assessed adolescents all medical options merely because the evidence base is difficult to build. They stress persistent distress, specialist assessment, informed consent, family involvement, fertility counselling and the ethical duty to weigh harm from treatment against harm from withholding it. They also argue that transgender young people require respectful care and that non-medical support alone will not meet every patient’s needs.

Critics argue that Germany has reached a more permissive clinical conclusion than the Nordic authorities despite accepting the same central problem: the evidence is uncertain and mostly observational. They emphasise the changed referral population, psychiatric comorbidity, autism, limited long-term data, uncertain discontinuation and regret data, and the irreversibility of some outcomes. On this view, the Nordic reports support a precautionary, research-led model in which psychosocial care is the default and medical intervention is exceptional.

Supporters of the Self-Determination Act regard it as a necessary removal of humiliating and disproportionate legal barriers to changing official documents. Critics distinguish legal recognition from medical care but argue that lowering the threshold for legal change by minors may shape family, school and clinical expectations at a stage when identity can still be developing. The statute itself does not resolve that disagreement because it expressly excludes medical treatment.

Interpretation

Beyond Gender’s reading is that Germany has acknowledged the Nordic evidence problem without following the Nordic precautionary conclusion. The S2k guideline contains serious safeguards: persistence, specialist expertise, parental involvement, fertility discussion, assessment of co-occurring difficulties and recorded uncertainty. But it still leaves a route to puberty suppression and cross-sex hormones outside the research-only or exceptional-case frameworks adopted in Sweden and, in different form, Finland.

The decisive distinction is methodological and institutional. SBU and UKOM foreground what cannot yet be known from the available evidence and make that uncertainty a reason to narrow routine practice. The German S2k document treats uncertainty as compatible with case-by-case clinical decisions reached through expert consensus. That is a genuine policy choice, not a difference in the underlying absence of randomised, long-term comparative evidence.

The Self-Determination Act should not be described as a medical-transition law. Its practical change is civil and administrative: it removes compulsory court proceedings and external expert reports for legal sex-entry and name changes. Nevertheless, law, schools, families and clinics do not operate in sealed compartments. For minors especially, a legal change can become part of a broader social pathway. That makes rigorous assessment, open-ended psychological care and reliable long-term outcome recording more important, not less.

Open questions

Germany’s central unanswered question is whether its consensus-led model will produce the long-term evidence that its own guideline says is uncertain. National registers should report not merely uptake of blockers and hormones, but diagnostic profiles, mental-health outcomes, physical outcomes, discontinuation, detransition, fertility decisions, satisfaction and regret, with sufficiently long follow-up and transparent denominators.

There is also a legal-policy question. The Self-Determination Act requires parental involvement for minors, but it permits court substitution of parental consent for those aged 14 and over. How courts will apply the “not contrary to the child’s welfare” test in contested cases remains a matter for case law rather than a settled consequence of the statute.

Finally, Europe needs clearer separation between three questions that are too often merged: respectful treatment in daily life, the legal recording of sex and names, and consent to interventions with potentially lifelong bodily consequences. The German record shows that a state may liberalise one of these domains while clinical evidence in another remains unsettled.

On the European timeline

Episodes on this subject

Where Did Psychotherapy Go Wrong? | Ian Cox

Why Anorexia is Just Like Gender Dysphoria...? A Conversation with Deanne Jade

When Sexual Fantasy Becomes Medical Treatment | Malcolm Clark